NFKB1 and cancer: Therapeutic inhibition of CCL2/CCR2 axis through NF-κB ablation, abrogates inflammatory monocyte recruitment and TAM infiltration in different mice models of several cancer types such as primary and metastatic breast cancer, HCC and lung cancer [204,208].